New York, New York--(Newsfile Corp. - July 18, 2025) - If you suffered a loss on your Sarepta Therapeutics, Inc. (NASDAQ: SRPT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:

https://zlk.com/pslra-1/sarepta-lawsuit-submission-form?prid=157259&wire=5&utm_campaign=5

or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.

THE LAWSUIT: A class action securities lawsuit was filed against Sarepta Therapeutics, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy's present and expanded approvals; and (iv) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements.

WHAT'S NEXT? If you suffered a loss in Sarepta stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/sarepta-lawsuit-submission-form?prid=157259&wire=5&utm_campaign=5 to learn about your rights to seek a recovery. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 17th FloorNew York, NY 10004jlevi@levikorsinsky.comTel: (212) 363-7500Fax: (212) 363-7171https://zlk.com/

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/259342

COMTEX_467430373/2523/2025-07-18T15:50:59